Behring's diagnostic sales up 14% in 1995
This article was originally published in Clinica
Executive Summary
Sales at German diagnostics manufacturer Behring increased 14% to DM 799 million ($540 million) in 1995, largely due to the acquisition of Syva last year (see Clinica No 641, p 1). The purchase and integration of Syva, cost-containment measures in healthcare and exchange rate movements are blamed for an operating loss of DM 14 million. Behring is a subsidiary of German chemicals company Hoechst.